Skip to content
2000
Volume 21, Issue 3
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Background

Rituximab (RTX) is used off-label for refractory cases of systemic lupus erythematosus (SLE) with extrarenal activity, including neurological and/or psychiatric (N/P) presentations. However, evidence from randomized controlled trials is limited.

Objective

This study aimed to conduct a pooled analysis of the effectiveness and safety of RTX therapy for adult refractory SLE with N/P manifestations.

Methods

Electronic searches in PubMed, Epistemonikos, and ICTRP databases and statistical analysis were conducted in May 2023.

Results

Electronic searches identified 20 studies (25 reports). A total of 59 patients (53 females; 90%) were included, with a mean age of 33.5±10.6 years and a median disease duration of 3.5 years (range, 0.08 to 25.0) who were followed up post-RTX therapy for a median time of 12 months (range, 3.0 to 46.2). The rate of clinical response (partial or major) was 90% (95% CI, 83 to 96) (n = 57 patients). A third of responders relapsed after a median time of 9.5 months (range, 3.0 to 33.0). Pooled pre-RTX/post-RTX scores for Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (n = 13) were 19±15/7±5 and for neurological British Isles Lupus Assessment Group (BILAG) (n = 29) were A/D (13), A/C (5), B/D (7), B/C (2), and A/A (2). Patients without mood disorder had a higher chance of clinical response (relative risk (RR) 1.4 (1.03 to 1.48)). Patients who benefited the most from RTX therapy were those with psychosis (a higher chance of major clinical response; RR 1.9 (1.02 to 2.34)), without acute confusional state (a lower chance of relapse; RR 0.08 (0.006 to 0.791)), and with disease duration <3 years (a lower chance of relapse; RR 0.18 (0.014 to 0.992)). Infection rate during treatment was 33% (7/21).

Conclusion

RTX therapy had good effectiveness. The pooled evidence for safety outcomes was limited and of low certainty.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971309959240722062141
2024-08-12
2025-09-01

  • From This Site

    /content/journals/crr/10.2174/0115733971309959240722062141
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TanakaY. KuboS. IwataS. YoshikawaM. NakayamadaS. B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus.Clin. Immunol.2018186212510.1016/j.clim.2017.07.01028789968
     [Google Scholar]
  2. PintoL.F. VelásquezC.J. PrietoC. MestraL. ForeroE. MárquezJ.D. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.Lupus201120111219122610.1177/096120331140927321784778
     [Google Scholar]
  3. Rydén-AulinM. BoumpasD. BultinkI. Callejas RubioJ.L. Caminal-MonteroL. CastroA. Colodro RuizA. DoriaA. DörnerT. Gonzalez-EchavarriC. GremeseE. HoussiauF.A. HuizingaT. InançM. IsenbergD. IulianoA. JacobsenS. Jimenéz-AlonsoJ. KovácsL. MarietteX. MoscaM. NivedO. OristrellJ. Ramos-CasalsM. RascónJ. Ruiz-IrastorzaG. Sáez-CometL. Salvador CervellóG. SebastianiG.D. SquatritoD. SzücsG. VoskuylA. van VollenhovenR. Off-label use of rituximab for systemic lupus erythematosus in Europe.Lupus Sci. Med.201631e00016310.1136/lupus‑2016‑00016327651920
     [Google Scholar]
  4. LuT.Y.T. NgK.P. CambridgeG. LeandroM.J. EdwardsJ.C.W. EhrensteinM. IsenbergD.A. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients.Arthritis Care Res.200961448248710.1002/art.2434119333973
     [Google Scholar]
  5. AlshaikiF. ObaidE. AlmuallimA. TahaR. El-haddadH. AlmoallimH. Outcomes of rituximab therapy in refractory lupus: A meta-analysis.Eur. J. Rheumatol.20185211812610.5152/eurjrheum.2018.1709630185361
     [Google Scholar]
  6. TerrierB. AmouraZ. RavaudP. HachullaE. JouenneR. CombeB. BonnetC. CacoubP. CantagrelA. De BandtM. FainO. FautrelB. GaudinP. GodeauB. HarléJ.R. HotA. KahnJ.E. LambotteO. LarrocheC. LéoneJ. MeyerO. Pallot-PradesB. PertuisetE. QuartierP. SchaerverbekeT. SibiliaJ. SomogyiA. SoubrierM. VignonE. Bader-MeunierB. MarietteX. GottenbergJ.E. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry.Arthritis Rheum.20106282458246610.1002/art.2754120506527
     [Google Scholar]
  7. IaccarinoL. BartoloniE. CarliL. CeccarelliF. ContiF. De VitaS. FerraccioliG. GaleazziM. GattoM. GerliR. GovoniM. GremeseE. IulianoA. MansuttiE. MoroniG. MoscaM. NalliC. NarettoC. PadovanM. PalmaL. RaffiottaF. RoccatelloD. TincaniA. ValesiniG. ZenM. DoriaA. Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian Multicentre Registry.Clin. Exp. Rheumatol.201533444945626053285
     [Google Scholar]
  8. Fernández-NebroA. de la FuenteJ.L.M. CarreñoL. IzquierdoM.G. TomeroE. Rúa-FigueroaI. Hernández-CruzB.E. NarváezJ. ÚcarE. OlivéA. ZeaA. Fernández-CastroM. Raya-ÁlvarezE. Pego-ReigosaJ.M. FreireM. Martínez-TaboadaV.M. Pérez-VenegasJ. Sánchez-AtrioA.I. Villa-BlancoI. Manrique-ArijaS. López-LongoF.J. CarreiraP.E. Martínez-PérezR. García-VicuñaR. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study.Lupus201221101063107610.1177/096120331244662722786985
     [Google Scholar]
  9. Ramos-CasalsM. García-HernándezF.J. de RamónE. CallejasJ.L. Martínez-BerriotxoaA. PallarésL. Caminal-MonteroL. Selva-O’CallaghanA. OristrellJ. HidalgoC. Pérez-AlvarezR. MicóM.L. MedranoF. Gómez de la TorreR. Díaz-LagaresC. CampsM. OrtegoN. Sánchez-RománJ. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.Clin. Exp. Rheumatol.201028446847620525449
     [Google Scholar]
  10. Liang MH, Corzillius M, Bae SC, et al The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.Arthritis Rheum.199942459960810.1002/1529‑0131(199904)42:4<599::AID‑ANR2>3.0.CO;2‑F10211873
     [Google Scholar]
  11. UntermanA. NolteJ.E.S. BoazM. AbadyM. ShoenfeldY. Zandman-GoddardG. Neuropsychiatric syndromes in systemic lupus erythematosus: A meta-analysis.Semin. Arthritis Rheum.201141111110.1016/j.semarthrit.2010.08.00120965549
     [Google Scholar]
  12. SarwarS. MohamedA.S. RogersS. Neuropsychiatric systemic lupus erythematosus: A 2021 update on diagnosis, management, and current challenges.Cureus202113917969
     [Google Scholar]
  13. MarinhoA. Delgado AlvesJ. FortunaJ. FariaR. AlmeidaI. AlvesG. Araújo CorreiaJ. CamparA. BrandãoM. CrespoJ. MaradoD. Matos-CostaJ. OliveiraS. SalvadorF. SantosL. SilvaF. FernandesM. VasconcelosC. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: Evidence- and practice-based guidance.Front. Immunol.202314111769910.3389/fimmu.2023.111769937138867
     [Google Scholar]
  14. Magro-ChecaC. ZirkzeeE.J. HuizingaT.W. Steup-BeekmanG.M. Management of neuropsychiatric systemic lupus erythematosus: Current approaches and future perspectives.Drugs201676445948310.1007/s40265‑015‑0534‑326809245
     [Google Scholar]
  15. PapachristosD.A. OonS. HanlyJ.G. NikpourM. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.Semin. Arthritis Rheum.2021511497110.1016/j.semarthrit.2020.12.00433360230
     [Google Scholar]
  16. NarváezJ. Ríos-RodriguezV. de la FuenteD. EstradaP. López-VivesL. Gómez-VaqueroC. NollaJ.M. Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence.Semin. Arthritis Rheum.201141336437210.1016/j.semarthrit.2011.06.00421875742
     [Google Scholar]
  17. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.BMJ2021372n7110.1136/bmj.n7133782057
     [Google Scholar]
  18. PageM.J. MoherD. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. McKenzieJ.E. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews.BMJ2021372n16010.1136/bmj.n16033781993
     [Google Scholar]
  19. IsenbergD.A. RahmanA. AllenE. FarewellV. AkilM. BruceI.N. D’CruzD. GriffithsB. KhamashtaM. MaddisonP. McHughN. SnaithM. TehL.S. YeeC.S. ZomaA. GordonC. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus.Rheumatology (Oxford)200544790290610.1093/rheumatology/keh62415814577
     [Google Scholar]
  20. BencivelliW. VitaliC. IsenbergD.A. SmolenJ.S. SnaithM.L. SciutoM. BombardieriS. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity.Clin. Exp. Rheumatol.19921055495541458711
     [Google Scholar]
  21. MoolaS. MunnZ. TufanaruC. Systematic reviews of etiology and risk. JBI Manual for Evidence SynthesisAdelaide, South AustraliaJBI Global Wiki2024
     [Google Scholar]
  22. ZhangJ. YuK.F. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.JAMA1998280191690169110.1001/jama.280.19.16909832001
     [Google Scholar]
  23. WalterS.D. YaoX. Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews.J. Clin. Epidemiol.200760884985210.1016/j.jclinepi.2006.11.00317606182
     [Google Scholar]
  24. SuurmondR. van RheeH. HakT. Introduction, comparison, and validation of Meta-essentials: A free and simple tool for meta-analysis.Res. Synth. Methods20178453755310.1002/jrsm.126028801932
     [Google Scholar]
  25. DerSimonianR. LairdN. Meta-analysis in clinical trials.Control. Clin. Trials19867317718810.1016/0197‑2456(86)90046‑23802833
     [Google Scholar]
  26. GalbraithR.F. Graphical display of estimates having differing standard errors.Technometrics198830327128110.1080/00401706.1988.10488400
     [Google Scholar]
  27. EggerM. SmithG.D. SchneiderM. MinderC. Bias in meta-analysis detected by a simple, graphical test.BMJ1997315710962963410.1136/bmj.315.7109.6299310563
     [Google Scholar]
  28. BeggC.B. MazumdarM. Operating characteristics of a rank correlation test for publication bias.Biometrics19945041088110110.2307/25334467786990
     [Google Scholar]
  29. ArmstrongD.J. McCarronM.T. WrightG.D. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).Rheumatol. Int.200626877177210.1007/s00296‑005‑0068‑116231119
     [Google Scholar]
  30. MehtaP. GuptaL. MuhammedH. MisraD.P. LawrenceA. AgarwalV. AggarwalA. MisraR. Spectrum of myelitis in systemic lupus erythematosus: Experience from a single tertiary care centre over 25 years.Mediterr. J. Rheumatol.2021314313810.31138/mjr.32.1.3134386700
     [Google Scholar]
  31. WenX. XuD. YuanS. ZhangJ. Transverse myelitis in systemic lupus erythematosus: A case report and systematic literature review.Autoimmun. Rev.202221610310310.1016/j.autrev.2022.10310335452852
     [Google Scholar]
  32. TanakaY. YamamotoK. TakeuchiT. NishimotoN. MiyasakaN. SumidaT. ShimaY. TakadaK. MatsumotoI. SaitoK. KoikeT. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.Mod. Rheumatol.200717319119710.3109/s10165‑007‑0565‑z17564773
     [Google Scholar]
  33. TokunagaM. SaitoK. KawabataD. ImuraY. FujiiT. NakayamadaS. TsujimuraS. NawataM. IwataS. AzumaT. MimoriT. TanakaY. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Ann. Rheum. Dis.200666447047510.1136/ard.2006.05788517107983
     [Google Scholar]
  34. SaitoK. NawataM. NakayamadaS. TokunagaM. TsukadaJ. TanakaY. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement.Lupus2003121079880010.1191/0961203303lu450xx14596432
     [Google Scholar]
  35. TokunagaM. FujiiK. SaitoK. NakayamadaS. TsujimuraS. NawataM. TanakaY. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.Rheumatology (Oxford)200544217618210.1093/rheumatology/keh44315494350
     [Google Scholar]
  36. SaitoK. NawataM. IwataS. TokunagaM. TanakaY. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus.Rheumatology (Oxford)200544111462146410.1093/rheumatology/kei07516105908
     [Google Scholar]
  37. LeandroM.J. CambridgeG. EdwardsJ.C. EhrensteinM.R. IsenbergD.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients.Rheumatology (Oxford)200544121542154510.1093/rheumatology/kei08016188950
     [Google Scholar]
  38. NgK.P. CambridgeG. LeandroM.J. EdwardsJ.C.W. EhrensteinM. IsenbergD.A. B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response.Ann. Rheum. Dis.20076691259126210.1136/ard.2006.06712417412738
     [Google Scholar]
  39. KhabbaziA. GhadakchiL. YazdaniY. HabibzadeE. MehrtabarS. KhalajiA. SLE -associated myelitis successfully treated by rituximab.Clin. Case Rep.20221011e662210.1002/ccr3.662236419577
     [Google Scholar]
  40. WeideR. HeymannsJ. PandorfA. KöpplerH. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy.Lupus2003121077978210.1191/0961203303lu449cr14596428
     [Google Scholar]
  41. GottenbergJ-E. GuillevinL. LambotteO. CombeB. AllanoreY. CantagrelA. LarrocheC. SoubrierM. BouilletL. DougadosM. FainO. FargeD. KyndtX. LortholaryO. MassonC. MouraB. RemyP. ThomasT. WendlingD. AnayaJ.M. SibiliaJ. MarietteX. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.Ann. Rheum. Dis.200564691392010.1136/ard.2004.02969415550531
     [Google Scholar]
  42. SmithK.G.C. JonesR.B. BurnsS.M. JayneD.R.W. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.Arthritis Rheum.20065492970298210.1002/art.2204616947528
     [Google Scholar]
  43. BirnbaumJ. KerrD. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus.Nat. Clin. Pract. Rheumatol.20084738138610.1038/ncprheum081818493269
     [Google Scholar]
  44. JónsdóttirT. GunnarssonI. RisseladaA. HenrikssonE.W. KlareskogL. van VollenhovenR.F. Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response.Ann. Rheum. Dis.200767333033410.1136/ard.2007.07909517827182
     [Google Scholar]
  45. TamimotoY. HoriuchiT. TsukamotoH. OtsukaJ. MitomaH. KimotoY. NakashimaH. MutaK. AbeY. KiyoharaC. UedaA. NagasawaK. YoshizawaS. ShimodaT. HaradaM. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: Immunological analysis of B cells, T cells and cytokines.Rheumatology (Oxford)200847682182710.1093/rheumatology/ken07118397955
     [Google Scholar]
  46. NasirS. KerrD.A. BirnbaumJ. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus.Arch. Neurol.20096691160116310.1001/archneurol.2009.19419752308
     [Google Scholar]
  47. EspinosaG. MendizábalA. MínguezS. Ramo-TelloC. CapelladesJ. OlivéA. CerveraR. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: Clinical, immunological, and radiological characteristics of 22 patients.Semin. Arthritis Rheum.201039424625610.1016/j.semarthrit.2008.09.00219022478
     [Google Scholar]
  48. Braun-MoscoviciY. Butbul-AvielY. GuralnikL. ToledanoK. MarkovitsD. RozinA. NahirM.A. Balbir-GurmanA. Rituximab: Rescue therapy in life-threatening complications or refractory autoimmune diseases: A single center experience.Rheumatol. Int.20133361495150410.1007/s00296‑012‑2587‑x23239037
     [Google Scholar]
  49. CarterLM IsenbergDA EhrensteinMR Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.Arthritis Rheum20136526729
     [Google Scholar]
  50. HickmanR.A. Hira-KazalR. YeeC.S. ToescuV. GordonC. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.Clin. Rheumatol.201534226327110.1007/s10067‑014‑2839‑025564308
     [Google Scholar]
  51. MackayG.A. CampbellS. JampanaR. CavanaghJ. A 50-year-old with rapid neuropsychiatric deterioration and choreiform movements.Pract. Neurol.201717323724010.1136/practneurol‑2016‑00148128119377
     [Google Scholar]
  52. IshikawaY. KasuyaT. IshikawaJ. FujiwaraM. KitaY. A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus.Ther. Clin. Risk Manag.2018141149115310.2147/TCRM.S16710929983569
     [Google Scholar]
  53. IwataS. SaitoK. HirataS. OhkuboN. NakayamadaS. NakanoK. HanamiK. KuboS. MiyagawaI. YoshikawaM. MiyazakiY. YoshinariH. TanakaY. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.Lupus201827580281110.1177/096120331774904729308726
     [Google Scholar]
  54. CheikhM.M. BahakimA.K. AljabriM.K. Neuropsychiatric lupus and lupus nephritis successfully treated with combined IVIG and rituximab: An alternative to standard of care.Case Rep Rheumatol202220225899188
     [Google Scholar]
  55. GhoshR. DasS. DeK. Magnetic resonance imaging-negative myeloneuropathy and bilateral facial paresis unfurling systemic lupus erythematosus.Qatar Med J2022202234210.5339/qmj.2022.42
     [Google Scholar]
  56. Ramos-CasalsM. SotoM.J. CuadradoM.J. KhamashtaM.A. Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases.Lupus200918976777610.1177/096120330910617419578100
     [Google Scholar]
  57. Md YusofM.Y. ShawD. El-SherbinyY.M. DunnE. RawstronA.C. EmeryP. VitalE.M. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.Ann. Rheum. Dis.201776111829183610.1136/annrheumdis‑2017‑21119128684557
     [Google Scholar]
/content/journals/crr/10.2174/0115733971309959240722062141
Loading
Rituximab Therapy for Adult Refractory Systemic Lupus Erythematosus with Neurological and/or Psychiatric Presentations: A PRISMA- Compliant Meta-Analysis
Curr. Rheumatol. Rev. 21, 336 (2025); https://doi.org/10.2174/0115733971309959240722062141
/content/journals/crr/10.2174/0115733971309959240722062141
/content/journals/crr/10.2174/0115733971309959240722062141
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publishers' website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): adult refractory; meta-analysis monoclonal antibody; neurological; psychiatric presentation; Rituximab therapy; systemic lupus erythematosus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test